Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Bicalutamide (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 03 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.